Genmab A/S, of Copenhagen, Denmark, said worldwide sales of multiple myeloma drug Darzalex (daratumumab) totaled $498 million for the third quarter, as reported by partner Johnson & Johnson, of New Brunswick, N.J., an increase of 57 percent over the third quarter of 2017. Genmab receives royalties under the companies' collaboration agreement.